Atypical fractures of proximal femur associated with prolonged use of bisphosphonates.

Article Sidebar

PDF (Español (España)) PDF_EN
Published: Aug 19, 2018
DOI: https://doi.org/10.15417/issn.1852-7434.2018.83.3.748
Keywords:
Hip fracture, osteoporosis, bisphosphonates.

Main Article Content

Yamile Vanina Neder
Hospital Privado Universitario de Córdoba
http://orcid.org/0000-0003-1360-6573
Alejandro Fazio
Hospital Privado Universitario de Córdoba
http://orcid.org/0000-0002-3807-0966
Pablo Valle
Hospital Privado Universitario de Córdoba
Facundo Faule
Hospital Privado Universitario de Córdoba
Mariano Finola
Hospital Privado Universitario de Córdoba

Abstract

IntroductionBisphosphonates are currently considered a first-choice treatment for osteoporotic disease. A number of adverse effects call into question its long-term administration, such as proximal femoral pathological fractures. The purposes of this study were to determine the relationship between consumption of bisphosphonates and atypical fractures, report the incidence of atypical fractures in our institution.MethodsRetrospective, observational study, case-control unpaired analysis. Patients >55 years old with femoral fractures admitted from January 1, 2009 to May 31, 2015 were included. Considered variables were: sex, age, type of fracture, use, type and time of consumption of bisphosphonates. Fractures were divided into typical: pertrochanteric, and femoral neck, and atypical: subtrochanteric and XXX. Atypical fractures were cases, and typical fractures functioned as controls.ResultsA total of 517 met the inclusion criteria and were included in the study. Forty-two fractures were atypical and 236 were typical. Female sex predominated (81.4% of cases, and 83% of controls). Average age was 76 and 80 years, respectively. Association with bisphosphonates was 44.2% of the cases, and 15.3% of controls (11.6& and 0.8% in pertrochanteric fractures, respectively).ConclusionsAlendronate was significantly associated with atypical femoral fractures. A relationship with length of consumption was not detected; however, incidence was higher after 4.5-5 years of use.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
Neder, Y. V., Fazio, A., Valle, P., Faule, F., & Finola, M. (2018). Atypical fractures of proximal femur associated with prolonged use of bisphosphonates. Revista De La Asociación Argentina De Ortopedia Y Traumatología, 83(3), 152-156. https://doi.org/10.15417/issn.1852-7434.2018.83.3.748
Issue
Vol 83 No 3 (2018)
Section
Clinical Research
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Manuscript acceptance by the Journal implies the simultaneous non-submission to any other journal or publishing house. The RAAOT is under the Licencia Creative Commnos Atribución-NoComercial-Compartir Obras Derivadas Igual 4.0 Internacional (CC-BY-NC.SA 4.0) (http://creativecommons.org/licences/by-nc-sa/4.0/deed.es). Articles can be shared, copied, distributed, modified, altered, transformed into a derivative work, executed and publicly communicated, provided a) the authors and the original publication (Journal, Publisher and URL) are mentioned, b) they are not used for commercial purposes, c) the same terms of the license are maintained.

In the event that the manuscript is approved for its next publication, the authors retain the copyright and will assign to the journal the rights of publication, edition, reproduction, distribution, exhibition and communication at a national and international level in the different databases. data, repositories and portals.

It is hereby stated that the mentioned manuscript has not been published and that it is not being printed in any other national or foreign journal.

The authors hereby accept the necessary modifications, suggested by the reviewers, in order to adapt the manuscript to the style and publication rules of this Journal.

References

1. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010;25:2267-9.

2. European Medicines Agency. European Medicines Agency concludes class review of bisphosphonates and atypical fractures. Disponible en:http://www.ema.europa.eu/ema/index.jspcurl=pages/medicines/human/publichealh_alerts/2011/04/human_pha_detail_000027.jsp&mid=WC0b01ac058001d126.

3. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res 2012; 27:243-54.

4. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296(24):2927-38.

5. Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013;28(8):1729-37.

6. McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday. Am J Med 2013;126:13-20.

7. Whitaker M, Guo J, Kehoe T, Benson G. Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012;366:2048-51.

8. Black DM, Bauer DC, Schwartz AV, Cummings SR, Rosen CJ. Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med 2012;366:2051-3.

Most read articles by the same author(s)